U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Showing 381 - 390 of 15963 results

Status:
Investigational
Source:
NCT00080132: Phase 2 Interventional Terminated Hypertriglyceridemia
(2004)
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Implitapide is a microsomal triglyceride transfer protein (MTP) inhibitor with antihyperlipidemic activity. Microsomal triglyceride transfer protein (MTP) is essential for the synthesis of both chylomicron in the intestine and very low-density lipoprotein in the liver. In an animal model, inhibition of MTP by implitapide reduced both total cholesterol and triglyceride levels and suppressed progression of atherosclerotic lesions in apolipoprotein E knockout mice fed a Western-type diet.
Status:
Investigational
Source:
INN:atromepine
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Atromepine (wider known as levomepate) is a levo isomer of tropine α-methyltropate. Experiments on animals have shown that this compound had marked anticholinergic action, possessed ganglionic-blocking activity and didn’t have any pathologic damages or teratogenic effects.
Status:
Investigational
Source:
NCT02511197: Early Phase 1 Interventional Unknown status Pulmonary Fibrosis, Unspecified
(2015)
Source URL:

Class (Stereo):
CHEMICAL (EPIMERIC)

Status:
Investigational
Source:
INN:cloticasone
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Cloticasone is a synthetic glucocorticoid corticosteroid, an analog of fluticasone. Cloticasone was discovered by Glaxo in the 1980s and claimed to be useful as an antiinflammation agent.
Status:
Investigational
Source:
INN:lividomycin
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Lividomycin is the antibacterial agent produced by Streptomyces lividus. It is aminoglycoside antibiotic. Lividomycin binds to bacterial ribosomes and inhibits protein synthesis. In vitro development of resistance to lividomycin in P. aeruginosa and M. tuberculosis was much slower than that to kanamycin, but was comparable in Staphylococcus aureus. Lividomycin showed a positive protecting effect for the experimental infections in mice with several bacteria such as S. aureus, P. aeruginosa, Klebsiella pneumoniae and Escherichia coli. It was fairly effective for the experimental infection with the kanamycin-resistant strains of E. coli and P. aeruginosa producing the kanamycin-phosphorylating enzyme.
Status:
Investigational
Source:
INN:tropabazate
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Tropabazate is a narcosis potentiator, tranquilliser.
Status:
Investigational
Source:
INN:ursulcholic acid [INN]
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Ursulcholic acid is a soluble form of ursodeoxycholic acid. It is an anticholinergic agent.
Status:
Investigational
Source:
INN:revatropate
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Revatropate is a muscarinic antagonist with selectivity for M1 and M3 receptor subtypes. Significant improvement in airway function was shown in horses with heaves after inhalation of revatropate, and it was found to be a safe and effective bronchodilator. Early clinical studies in chronic obstructive airway disease (COAD) patients also showed that inhaled revatropate was an effective bronchodilator, and well tolerated.
Status:
Investigational
Source:
NCT04172532: Phase 1/Phase 2 Interventional Recruiting Locally Advanced Pancreatic Adenocarcinoma
(2021)
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)


Status:
Investigational
Source:
Am J Clin Oncol. Apr 2001;24(2):150-4.: Phase 2 Human clinical trial Completed Prostatic Neoplasms
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Menogaril is a semisynthetic derivative of the anthracycline antineoplastic antibiotic nogalamycin. Biochemical studies indicated that, in comparison to doxorubicin, menogaril is bound weakly to DNA, inhibits RNA synthesis less, and has different cell cycle phase-specific cytotoxicity. Menogaril acts as a cleavable complex-stabilizing topoisomerase II inhibitor. Menogaril has been studied in the treatment of various cancers.